The Statin+Ezetimibe combination market is pouring out a blockbuster.
According to IQVIA, the Statin+Ezetimibe combination market expanded to KRW 330 billion last year with 20% growth despite the COVID-19.
As a result, large-scale products that record more than KRW 10 billion per year have emerged. The number of blockbusters nearly doubled from 5 to 9 products last year.
Rosuzet (Hanmi Pharmaceutical), which took the lead with KRW 53.2 billion in 2019, expanded its sales to KRW 63.1 billion over KRW 60 billion last year.
Atozet, which exceeded KRW 50 billion in 2019 along with Rosuzet, also grew to KRW 58.9 billion, while Rosuvamibe (Yuhan) swelled from KRW 33.8 billion to KRW 38.6 billion, and Rovazet (HK inno.N) from KRW 14.6 billion to KRW 16.4 billion.
On the other hand, Vytorin (MSD Korea), which pioneered the Ezetimibe+Statin combination market, saw its pullback, and its sales decreased to KRW 17.1 billion.
While the existing KRW 10 billion products remained blockbusters, four new drugs, including Crezet (Daewoong Pharmaceutical), Daviduo (Green Cross), Esuba (Huons), and Roze Duo (Jeil Pharmaceutical), have joined the blockbuster ranks.
Among them, Crezet, which was the closest to the KRW 10 billion mark at KRW 9.4 billion in 2019, rose to KRW 15.3 billion, breaking through the KRW 15 billion mark at once.
Daviduo nearly doubled its size to KRW 11.3 billion, Esuba from KRW 8.3 billion, and Roze Duo from KRW 7.8 billion to KRW 10.7 billion.
In particular, eight of the Statin+Ezetimibe combination therapies, excluding Vytorin, posted double-digit growth, and four products that newly climbed to KRW 10 billion mark recorded a growth rate exceeding 20%.
Duoroban (Kyung Dong Pharma) fell back to KRW 9 billion from KRW 9.1 billion and could not make it blockbuster.
However, Crestibe (HUTECS) seems to enter a blockbuster with more than 50% growth from KRW 5.2 billion to KRW 8.1 billion.
Rostorin (Hana Pharm) and Clowzet (Daewon Pharmaceutical Company) entered KRW 5 billion mark with KRW 6.1 billion and KRW 5 billion.
